Infographic shows why investors are psyched about psychedelic stocks

The stage seems set for a psychedelic revolution—and savvy investors are paying attention


Illustration by kragle/ iStock/Getty Images Plus.


It’s no surprise to regular readers of this website that psychedelics are becoming a very big deal. Much of the buzz is rooted in a growing body of research suggesting that psilocybin, MDMA, and other substances can be effective in treating conditions such as depression and PTSD.

Last year, close to 15,000 Canadians signed a petition to allow the use of plants and fungi with psychedelic properties. The federal government rejected this call for decriminalization, but has granted exemptions for end-of-life psilocybin therapy.

Canada’s health minister has also approved 17 health-care professionals to possess and use psilocybin for research and training purposes.

In the United States, meanwhile, voters passed several measures as part of the November 3, 2020 election, as CannCentral reported.

For example, voters in Oregon passed Measure 109, which legalizes the use of psilocybin in therapy. With the passage of the measure, Oregon became the first state in the U.S. to legalize psilocybin therapy.

In addition, voters in the District of Columbia, home of the U.S. capital, supported Initiative 81, which decriminalized a range of psychedelic substances. These include ibogaine, dimethyltryptamine, mescaline, psilocybin, and psilocyn.

Investors are paying attention

The stage seems set for a psychedelic revolution—and savvy investors are paying attention. A new infographic from Visual Capitalist shows phenomenal growth in the price performance of nine prominent psychedelic stocks in 2020.

The infographic is based on data released on September 4, 2020 by YCharts and Frontiers in Psychology.

Check out the infographic below:

Infographic by Visual Capitalist. Click to see full-sized image.

In an article accompanying the infographic, Aran Ali notes the following:

Some of the earlier research and studies on psychedelics are expected to be released by mid-2021, and investors are already getting ahead of this in optimistic anticipation. This is evident in the valuations of some of these companies, which in some cases are already reaching a billion dollars.

“Welcome to the shroom boom,” Ali concludes.

Leave your opinion for the editor...We read everything!

Your email address will not be published. Required fields are marked *